Clinical features of patients with left atrial thrombus undergoing anticoagulant therapy
- 188 Downloads
Left atrial (LA) thrombus was sometimes found by transesophageal echocardiography (TEE) in non-valvular atrial fibrillation (AF), even in the setting of continuous warfarin therapy. A D-dimer cutoff level of 0.50 μg/mL appears to be a useful marker to rule out venous vein thrombosis. This study analyzed the clinical features of patients with LA thrombi who received anticoagulant therapy and whether the D-dimer test is useful to exclude LA thrombus.
Two hundred twenty-five consecutive patients with AF (149 with paroxysmal and 76 with persistent) were enrolled. All patients received continuous warfarin therapy with the prothrombin time-international normalized ratio (PT-INR) between 1.6 and 3.0 for more than 3 months and TEE was performed.
LA thrombi were present in 23 and absent in 202 patients. Age, gender, and PT-INR (1.96 ± 0.59 vs. 1.98 ± 0.53) were not different between the two groups. Persistent AF (65 vs. 30%; p < 0.005), LA diameter (44 ± 5 vs. 40 ± 7 mm; p < 0.005), ejection fraction (57 ± 13 vs. 65 ± 9%; p < 0.005), brain natriuretic peptide levels (203 ± 209 vs. 105 ± 166 pg/mL; p < 0.05), D-dimer (0.55 ± 0.70 vs. 0.16 ± 0.20 μg/mL; p < 0.001), LA appendage flow velocity (33 ± 15 vs. 54 ± 19 cm/s; p < 0.001), CHADS2 scores (2 ± 1 vs. 1 ± 1; p < 0.005), and CHA2DS2-VASc scores (3 ± 2 vs. 2 ± 1; p < 0.005) were significantly different in both groups. Although multivariate analysis showed that D-dimer and LA appendage flow velocity were significant independent predictors of LA thrombus, D-dimer levels below 0.5 μg/mL were found in 19 of 23 patients with LA thrombi.
D-dimer levels below 0.5 μg/mL is not enough to rule out LA thrombus in AF patients with well-controlled anticoagulation.
KeywordsAtrial fibrillation Catheter ablation Thrombus Transesophageal echocardiography Warfarin
- 1.Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 114, e257–e354.PubMedCrossRefGoogle Scholar
- 3.Joint Working Groups: The Japanese Circulation Society, The Japanese College of Cardiology, The Japanese Society of Electrocardiology, and The Japanese Heart Rhythm Society. (2008). Guidelines for pharmacotherapy of atrial fibrillation (JSC 2008). Circulation Journal, 72(Suppl. IV), 1639–1658.Google Scholar
- 4.European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., et al. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). EP, 12, 1360–1420.Google Scholar
- 5.Műgge, A., Daniel, W. G., Hausman, D., Gődke, J., Wagenbreth, I., & Lichtlen, P. R. (1990). Diagnosis of left atrial appendage thrombi by transesophageal echocardiography: clinical implication and follow up. American Journal of Cardiac Imaging, 41, 73–79.Google Scholar
- 7.Tabata, T., Oki, T., Iuchi, A., Yamada, H., Manabe, K., Fukuda, K., et al. (1997). Evaluation of left atrial appendage function by measurement of changes in flow velocity patterns of after electrical cardioversion in patients with isolated atrial fibrillation. The American Journal of Cardiology, 79, 615–620.PubMedCrossRefGoogle Scholar
- 9.Stroke Prevention in Atrial Fibrillation Investigators. (1996). Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet, 348, 633–638.CrossRefGoogle Scholar
- 10.Seidl, K., Rameken, M., Drögemüller, A., Vater, M., Brandt, A., Schwacke, H., et al. (2002). Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. Journal of the American College of Cardiology, 39, 1436–1442.PubMedCrossRefGoogle Scholar
- 12.Prystowsky, E. N., Benson, D. W., Jr., Fuster, V., Hart, R. G., Kay, G. N., Myerburg, R. J., et al. (1996). Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation, 93, 1262–1277.PubMedGoogle Scholar